Interparfums Inc header image

Interparfums Inc

IPAR

Equity

ISIN null / Valor 833467

NASDAQ (2025-11-21)
USD 80.61-0.49%

Interparfums Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Inter Parfums, Inc., established in 1982, operates within the global fragrance industry, specializing in the production and distribution of an extensive range of prestige fragrance and fragrance-related products. The company conducts its operations through two main segments: European operations, managed by its 72% owned subsidiary Interparfums SA, and United States-based operations. Inter Parfums holds license agreements with various brand owners, producing and distributing products for a portfolio of prestige brands such as Boucheron, Coach, Jimmy Choo, and Montblanc, among others. These products are available in over 120 countries. European operations account for approximately 65% of the company's net sales, with the remaining 35% generated by its U.S. operations, which include brands like Abercrombie & Fitch, Anna Sui, and Donna Karan. The company focuses on leveraging the strong market presence of these brands, introducing new fragrance families every few years alongside seasonal and limited-edition fragrances to maintain consumer interest and market relevance.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (21.11.2025):

Interparfums, Inc. reported its results for the fourth quarter of 2023 and announced record full-year 2023 results. The company said it delivered its 2023 target earnings per share, raised its cash dividend by 20%, and affirmed its financial guidance for 2024.

Quarter and full-year results

The company reported fourth-quarter 2023 results and described 2023 as a record full-year performance (specific revenue and profit figures were not provided in the excerpt).

Earnings per share

Interparfums stated it "delivers 2023 target EPS," indicating it met its previously announced earnings-per-share target for 2023 (no numeric EPS was included in the provided text).

Dividend

The board approved a 20% increase in the cash dividend following the 2023 results.

2024 guidance

The company affirmed its guidance for 2024 (the excerpt did not include the detailed guidance range or targets).

Context from prior year

The release also references prior announcements that 2022 produced record fourth-quarter and full-year results and that the company had previously raised 2023 net sales and earnings guidance and increased the cash dividend by 25% for that period.

Summarized from source with an LLMView Source

Key figures

-38.3%1Y
-8.93%3Y
52.1%5Y

Performance

32.7%1Y
34.1%3Y
34.4%5Y

Volatility

Market cap

2589 M

Market cap (USD)

Daily traded volume (Shares)

445,972

Daily traded volume (Shares)

1 day high/low

130.95 / 127.9

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%CHF 96.58
National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.42%USD 130.44
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.94%EUR 1.05
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Baxter International Inc
Baxter International Inc Baxter International Inc Valor: 911702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.11%USD 18.31
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%CHF 67.10
Astrana Health Inc
Astrana Health Inc Astrana Health Inc Valor: 28041888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
10.62%USD 22.50
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20